Nancy Pryer

Nancy Pryer, Ph.D., has contributed to the discovery and development of eight marketed drugs in oncology and rare diseases. She joined Ambagon from DayOne Biopharmaceuticals, where she was CSO. Prior to DayOne, Nancy was Chief Development Officer at Nurix Therapeutics, a leader in targeted protein degradation. There, she was responsible for advancing two lead candidate programs through preclinical development and building the clinical development function. Nancy previously served as Vice President of Translational Sciences at BioMarin Pharmaceutical, where she led the company’s efforts in biomarker discovery, bioanalytics, immunogenicity assessment, and clinical pharmacology. Prior to BioMarin, she held leadership roles in oncology drug discovery and translational development at Novartis Institutes for Biomedical Research where her team was responsible for the early discovery activities for BRAFTOVI® (encorafenib), Raven, SUGEN, and Onyx Pharmaceuticals where she led the team in the discovery of IBRANCE® (palbociclib). Nancy earned her Ph.D. in Biology from the University of North Carolina, Chapel Hill, and completed post-doctoral work in the lab of Nobel prize winner Randy Schekman at the University of California, Berkeley.